Children with both atopic dermatitis and food allergy have stratum corneum abnormalities that distinguish them from other atopic dermatitis endotypes and children without atopic disease.
The FDA has accepted Priority Review Dupixent as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis.
Certain intranasal corticosteroids may place patients with allergic rhinitis at a higher risk for epistaxis.
The FDA has granted Fast Track status to ARS-1, an investigational intranasal epinephrine spray being developed to treat severe allergic reactions.
Approximately 32 million people in the United States have a documented penicillin allergy. More than 95% of them can be treated safely with penicillin according to a review published in JAMA.
The product will be made available first in institutions followed by a launch in the retail setting.
To investigate the incidence of anaphylaxis after vaccination, study authors reviewed data submitted to the Vaccine Adverse Event Reporting System (VAERS) between 1990 and 2016.
Tivic Health Systems announced that ClearUP Sinus Pain Relief has been cleared by the Food and Drug Administration (FDA) for the treatment of sinus pain due to allergic rhinitis, or hay fever, in adults aged ≥18 years.